COGENT BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.02 USD | +0.17% |
|
-10.28% | +2.38% |
| Feb. 27 | North American Morning Briefing : Stock Futures -2- | DJ |
| Feb. 26 | Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Cogent Bioscience...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Companyâs clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.02
USD
Average target price
16.7
USD
Spread / Average Target
+177.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.38% | 576M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Transcript : Cogent Biosciences, Inc. - Special Call
